Evidence map›Paper›PMID 27111450›Full record

ArticlePloS one2016

Endothelial Cell-Selective Adhesion Molecule Expression in Hematopoietic Stem/Progenitor Cells Is Essential for Erythropoiesis Recovery after Bone Marrow Injury.

Takao Sudo, Takafumi Yokota, Daisuke Okuzaki, Tomoaki Ueda, Michiko Ichii, Tomohiko Ishibashi, Tomomi Isono, Yoko Habuchi, Kenji Oritani, Yuzuru Kanakura

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Takao SudoDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Takafumi YokotaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Daisuke OkuzakiDNA Chip Development Center, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Tomoaki UedaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Michiko IchiiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Tomohiko IshibashiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Tomomi IsonoDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yoko HabuchiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Kenji OritaniDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yuzuru KanakuraDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Osaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous red blood cells are generated every second from proliferative progenitor cells under a homeostatic state. Increased erythropoietic activity is required after myelo-suppression as a result of chemo-radio therapies. Our previous study revealed that the endothelial cell-selective adhesion molecule (ESAM), an authentic hematopoietic stem cell marker, plays essential roles in stress-induced hematopoiesis. To determine the physiological importance of ESAM in erythroid recovery, ESAM-knockout (KO) mice were treated with the anti-cancer drug, 5-fluorouracil (5-FU). ESAM-KO mice experienced severe and prolonged anemia after 5-FU treatment compared to wild-type (WT) mice. Eight days after the 5-FU injection, compared to WT mice, ESAM-KO mice showed reduced numbers of erythroid progenitors in bone marrow (BM) and spleen, and reticulocytes in peripheral blood. Megakaryocyte-erythrocyte progenitors (MEPs) from the BM of 5-FU-treated ESAM-KO mice showed reduced burst forming unit-erythrocyte (BFU-E) capacities than those from WT mice. BM transplantation revealed that hematopoietic stem/progenitor cells from ESAM-KO donors were more sensitive to 5-FU treatment than that from WT donors in the WT host mice. However, hematopoietic cells from WT donors transplanted into ESAM-KO host mice could normally reconstitute the erythroid lineage after a BM injury. These results suggested that ESAM expression in hematopoietic cells, but not environmental cells, is critical for hematopoietic recovery. We also found that 5-FU treatment induces the up-regulation of ESAM in primitive erythroid progenitors and macrophages that do not express ESAM under homeostatic conditions. The phenotypic change seen in macrophages might be functionally involved in the interaction between erythroid progenitors and their niche components during stress-induced acute erythropoiesis. Microarray analyses of primitive erythroid progenitors from 5-FU-treated WT and ESAM-KO mice revealed that various signaling pathways, including the GATA1 system, were impaired in ESAM-KO mice. Thus, our data demonstrate that ESAM expression in hematopoietic progenitors is essential for erythroid recovery after a BM injury.

Indexed as

AnimalsAntimetabolites, AntineoplasticBone Marrow CellsBone Marrow TransplantationCell Adhesion MoleculesCell CommunicationErythropoiesisFemaleFluorouracilGATA1 Transcription FactorGene Expression ProfilingGene Expression RegulationHematopoietic Stem CellsMacrophagesMaleMiceAntimetabolites, AntineoplasticCell Adhesion MoleculesEsam protein, mouseFluorouracilGata1 protein, mouseGATA1 Transcription Factor

Identifiers

PMID27111450
PMCPMC4844162
OpenAlexW2344323747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.